Mathew Calder

Title: Mathew Calder: Innovator in Tyrosine Kinase Inhibition

Introduction

Mathew Calder is a notable inventor based in Cheshire, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that inhibit Bruton's tyrosine kinase. With a total of 2 patents, his work is pivotal in advancing treatments for various diseases.

Latest Patents

Calder's latest patents focus on pyrazolopyrimidine derivatives that serve as inhibitors of Bruton's tyrosine kinase (BTK). These compounds are designed to target and inhibit BTK, which plays a crucial role in several immunological diseases and cancers, including lymphoma and leukemia. The invention outlines the potential therapeutic applications of these compounds, emphasizing their importance in treating conditions that can be managed through BTK inhibition.

Career Highlights

Mathew Calder is currently associated with Loxo Oncology, Inc., where he continues to innovate in the field of oncology. His expertise in developing targeted therapies has positioned him as a key figure in the fight against cancer. His contributions are recognized within the scientific community, and his patents reflect his commitment to improving patient outcomes.

Collaborations

Calder has worked alongside notable colleagues, including Nicolas E S Guisot and Nicolas Guisot. These collaborations have fostered a productive environment for research and development, leading to advancements in therapeutic strategies.

Conclusion

Mathew Calder's work in developing inhibitors of Bruton's tyrosine kinase showcases his dedication to innovation in the medical field. His contributions are vital for the advancement of treatments for serious health conditions.